Literature DB >> 23530966

Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension.

Nerea Fernández-Ros1, Nuno Silva, Jose Ignacio Bilbao, Mercedes Iñarrairaegui, Alberto Benito, Delia D'Avola, Macarena Rodriguez, Fernando Rotellar, Fernando Pardo, Bruno Sangro.   

Abstract

BACKGROUND: Post-treatment contralateral hemiliver hypertrophy has created an interest in lobar liver radioembolization (RE) as a pre-surgery tool.
METHODS: Liver and spleen volumes and function were studied in 83 patients submitted to partial liver volume RE at 4-8 weeks (T1), 10-26 weeks (T2), and >26 weeks (T3) after RE.
RESULTS: More than half of the patients had cirrhosis with hepatocellular carcinoma. The main finding was a progressive increase in the volume of the spared hemiliver (mean absolute increase at T3: 230 ml). The percentage of patients in whom the baseline ratio of spared volume to total liver volume was <40% dropped from 56.6% at baseline to 29.4% at T2 (P < 0.001). A significant and progressive increase in spleen volume but not in portal vein diameter was also observed. A small percentage of patients developed hypersplenism, mostly those without cirrhosis (16.0% at T2). Six patients (five with portal vein thrombosis, cirrhosis or both) developed signs of portal hypertension by T2.
CONCLUSIONS: The present results warrant further studies to better elucidate the mechanism underlying this phenomenon of spared hemiliver hypertrophy and to investigate its role as an alternative to portal vein embolization in the management of patients with potentially resectable liver tumours.
© 2013 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23530966      PMCID: PMC3945850          DOI: 10.1111/hpb.12095

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  38 in total

1.  Sequential arterial and portal vein embolizations before right hepatectomy in patients with cirrhosis and hepatocellular carcinoma.

Authors:  S Ogata; J Belghiti; O Farges; D Varma; A Sibert; V Vilgrain
Journal:  Br J Surg       Date:  2006-09       Impact factor: 6.939

Review 2.  Preoperative portal vein embolization: indications and technical considerations.

Authors:  Thierry de Baere; Alban Denys; David C Madoff
Journal:  Tech Vasc Interv Radiol       Date:  2007-03

Review 3.  Controversies in the use of portal vein embolization.

Authors:  Thomas M van Gulik; Jacomina W van den Esschert; Wilmar de Graaf; Krijn P van Lienden; Olivier R C Busch; Michal Heger; Otto M van Delden; Johan S Laméris; Dirk J Gouma
Journal:  Dig Surg       Date:  2009-02-12       Impact factor: 2.588

Review 4.  Radioembolization for hepatocellular carcinoma.

Authors:  Bruno Sangro; Mercedes Iñarrairaegui; Jose I Bilbao
Journal:  J Hepatol       Date:  2011-08-02       Impact factor: 25.083

5.  Hepatic toxicity after radioembolization of the liver using (90)Y-microspheres: sequential lobar versus whole liver approach.

Authors:  Ricarda Seidensticker; Max Seidensticker; Robert Damm; Konrad Mohnike; Kerstin Schütte; Peter Malfertheiner; Mark Van Buskirk; Maciej Pech; Holger Amthauer; Jens Ricke
Journal:  Cardiovasc Intervent Radiol       Date:  2011-10-26       Impact factor: 2.740

Review 6.  Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations.

Authors:  Riad Salem; Kenneth G Thurston
Journal:  J Vasc Interv Radiol       Date:  2006-08       Impact factor: 3.464

7.  Transsinusoidal portal vein embolization with ethylene vinyl alcohol copolymer (Onyx): a feasibility study in pigs.

Authors:  Maarten L J Smits; Peter Vanlangenhove; Emiel J C Sturm; Maurice A A J van den Bosch; Monirath Hav; Marleen Praet; Maarten A D Vente; Frédéric R Snaps; Luc Defreyne
Journal:  Cardiovasc Intervent Radiol       Date:  2011-10-07       Impact factor: 2.740

Review 8.  Liver metastases from colorectal cancer: radioembolization with systemic therapy.

Authors:  Nils H Nicolay; David P Berry; Ricky A Sharma
Journal:  Nat Rev Clin Oncol       Date:  2009-11-03       Impact factor: 66.675

9.  Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization.

Authors:  S Hayashi; Y Baba; K Ueno; M Nakajo; F Kubo; S Ueno; T Aikou; T Komokata; N Nakamura; R Sakata
Journal:  Acta Radiol       Date:  2007-09       Impact factor: 1.990

10.  Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections.

Authors:  Seza A Gulec; Kenneth Pennington; Michael Hall; Yuman Fong
Journal:  World J Surg Oncol       Date:  2009-01-08       Impact factor: 2.754

View more
  19 in total

Review 1.  Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know.

Authors:  Alexander Villalobos; Mohamed M Soliman; Bill S Majdalany; David M Schuster; James Galt; Zachary L Bercu; Nima Kokabi
Journal:  Semin Intervent Radiol       Date:  2020-12-11       Impact factor: 1.513

2.  Radioembolization as an adjunct therapy to the resection of liver tumors.

Authors:  Mercedes Iñarrairaegui; Bruno Sangro
Journal:  Hepat Oncol       Date:  2015-11-06

Review 3.  Radioembolization for hepatocellular carcinoma: current role and future directions - the medical oncologist's perspective.

Authors:  Peter Gibbs; Jeanne Tie; Lourens Bester
Journal:  Hepat Oncol       Date:  2015-04-20

Review 4.  [Contralateral hepatic hypertrophy following unilateral yttrium-90 radioembolization : Implications for liver surgery].

Authors:  B Garlipp; M Seidensticker; D Jechorek; H Ptok; C J Bruns; J Ricke
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

Review 5.  Contra-lateral liver lobe hypertrophy after unilobar Y90 radioembolization: an alternative to portal vein embolization?

Authors:  Jin-Yao Teo; Brian K P Goh
Journal:  World J Gastroenterol       Date:  2015-03-21       Impact factor: 5.742

Review 6.  Optimization of the future remnant liver: review of the current strategies in Europe.

Authors:  Riccardo Memeo; Maria Conticchio; Emmanuel Deshayes; Silvio Nadalin; Astrid Herrero; Boris Guiu; Fabrizio Panaro
Journal:  Hepatobiliary Surg Nutr       Date:  2021-06       Impact factor: 7.293

Review 7.  A systematic review of contralateral liver lobe hypertrophy after unilobar selective internal radiation therapy with Y90.

Authors:  Jin-Yao Teo; John C Allen; David C Ng; Su-Pin Choo; David W M Tai; Jason P E Chang; Foong-Khoon Cheah; Pierce K H Chow; Brian K P Goh
Journal:  HPB (Oxford)       Date:  2015-12-11       Impact factor: 3.647

Review 8.  Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus.

Authors:  Andrew Kennedy; Daniel B Brown; Jonas Feilchenfeldt; John Marshall; Harpreet Wasan; Marwan Fakih; Peter Gibbs; Alexander Knuth; Bruno Sangro; Michael C Soulen; Gianfranco Pittari; Ricky A Sharma
Journal:  J Gastrointest Oncol       Date:  2017-12

Review 9.  Selective Internal Radiation Therapy (SIRT) as Conversion Therapy for Unresectable Primary Liver Malignancies.

Authors:  Alessandro Cucchetti; Alberta Cappelli; Giorgio Ercolani; Cristina Mosconi; Matteo Cescon; Rita Golfieri; Antonio Daniele Pinna
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

10.  Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience.

Authors:  Marco Tabone; Amedeo Calvo; Nadia Russolillo; Serena Langella; Paolo Carbonatto; Roberto Lo Tesoriere; Elisa Richetta; Riccardo Pellerito; Alessandro Ferrero
Journal:  J Gastrointest Oncol       Date:  2020-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.